Literature DB >> 1505770

C-myc oncogene expression in ocular melanomas.

J A Royds1, R M Sharrard, M A Parsons, J Lawry, R Rees, D Cottam, B Wagner, I G Rennie.   

Abstract

We have investigated the expression of c-myc in 24 ocular melanomas by immunohistochemistry, using two monoclonal antibodies raised against a mid-sequence portion of the c-myc product (6E10) and against the C-terminus (9E10). The results were compared with other putative prognostic factors, including tumour size, cell type, proliferation index (determined by flow cytometry), and ploidy, as well as immunohistochemical staining for HMB-45 and S-100 antigens. Staining, often focal, for c-myc was found in both the nucleus and the cytoplasm of a proportion of the cells in most tumours studied. Total cell staining for myc protein correlated with proliferative index in diploid tumours; seven out of nine aneuploid and mixed aneuploid/diploid cells showed strong staining in at least one cellular compartment. A positive correlation with myc expression was also found for HMB-45 staining, but not for cell type or staining for S-100. The results support the hypothesis that myc protein is involved in cellular proliferation in uveal melanomas and indicate that immunohistochemistry for myc antigen may be a useful prognostic marker in these tumours.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505770     DOI: 10.1007/bf00165947

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  23 in total

1.  Analysis of DNA sequences present in complexes of v-Myc and cellular DNA.

Authors:  U Lorenz; E Sock; F Grummt; K Moelling
Journal:  Oncogene       Date:  1991-01       Impact factor: 9.867

2.  c-myc protein can be substituted for SV40 T antigen in SV40 DNA replication.

Authors:  S M Iguchi-Ariga; T Itani; M Yamaguchi; H Ariga
Journal:  Nucleic Acids Res       Date:  1987-06-25       Impact factor: 16.971

Review 3.  The molecular genetics of cancer.

Authors:  J M Bishop
Journal:  Science       Date:  1987-01-16       Impact factor: 47.728

4.  HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma.

Authors:  B R Smoller; N S McNutt; A Hsu
Journal:  Am J Surg Pathol       Date:  1989-08       Impact factor: 6.394

5.  Alterations in growth properties of human papilloma virus type 16 immortalised human cervical keratinocyte cell line correlate with amplification and overexpression of c-myc oncogene.

Authors:  T Crook; I Greenfield; J Howard; M Stanley
Journal:  Oncogene       Date:  1990-04       Impact factor: 9.867

6.  Prognostic factors in choroidal and ciliary body melanomas.

Authors:  H F Shammas; F C Blodi
Journal:  Arch Ophthalmol       Date:  1977-01

7.  Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product.

Authors:  A K Rustgi; N Dyson; R Bernards
Journal:  Nature       Date:  1991-08-08       Impact factor: 49.962

8.  DNA content abnormalities and prognosis in uveal melanoma.

Authors:  W J Meecham; D H Char
Journal:  Arch Ophthalmol       Date:  1986-11

9.  Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma.

Authors:  N G Ordóñez; X L Ji; R C Hickey
Journal:  Am J Clin Pathol       Date:  1988-10       Impact factor: 2.493

10.  DNA replication origin and transcriptional enhancer in c-myc gene share the c-myc protein binding sequences.

Authors:  H Ariga; Y Imamura; S M Iguchi-Ariga
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

View more
  8 in total

1.  Deregulation of the Rb and p53 pathways in uveal melanoma.

Authors:  M A Brantley; J W Harbour
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 2.  Conjunctival melanoma in Southwestern Nigeria: a case series and review of literature.

Authors:  Oluyemi Fasina; Olayiwola A Oluwasola
Journal:  Int Ophthalmol       Date:  2017-06-19       Impact factor: 2.031

3.  c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.

Authors:  J S Chana; G D Wilson; I A Cree; R A Alexander; N Myatt; M Neale; A J Foss; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

4.  Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma.

Authors:  C M Mooy; G P Luyten; P T de Jong; T M Luider; T Stijnen; F van de Ham; C C van Vroonhoven; F T Bosman
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

Review 5.  Molecular prognostic testing and individualized patient care in uveal melanoma.

Authors:  J William Harbour
Journal:  Am J Ophthalmol       Date:  2009-10-02       Impact factor: 5.258

6.  BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.

Authors:  Grazia Ambrosini; Ashley D Sawle; Elgilda Musi; Gary K Schwartz
Journal:  Oncotarget       Date:  2015-10-20

7.  Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Authors:  Gülçin Gezgin; Mehmet Dogrusöz; T Huibertus van Essen; Wilhelmina G M Kroes; Gregorius P M Luyten; Pieter A van der Velden; Vonn Walter; Robert M Verdijk; Thorbald van Hall; Sjoerd H van der Burg; Martine J Jager
Journal:  Cancer Immunol Immunother       Date:  2017-04-08       Impact factor: 6.968

8.  Identification of Cancer Stem Cell Subpopulations in Head and Neck Metastatic Malignant Melanoma.

Authors:  Vithushiya Yoganandarajah; Josie Patel; Bede van Schaijik; Nicholas Bockett; Helen D Brasch; Erin Paterson; Dalice Sim; Paul F Davis; Imogen M Roth; Tinte Itinteang; Swee T Tan
Journal:  Cells       Date:  2020-01-30       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.